Want to see HK:2162 full AI Analyst Report?
Keymed Biosciences, Inc. (2162) Financial Statements
Keymed Biosciences, Inc. Financial Overview
Keymed Biosciences, Inc.'s market cap is currently $18.82B. The company's EPS TTM is $2.78; its P/E ratio is 20.46; Keymed Biosciences, Inc. is scheduled to report earnings on March 30, 2027, and the estimated EPS forecast is $-1.42. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 697.77M | $ 428.12M | $ 354.10M | $ 100.06M | $ 110.27M |
| Gross Profit | $ 516.51M | $ 415.92M | $ 317.22M | $ 97.48M | $ 93.07M |
| Operating Income | $ -584.85M | $ -618.10M | $ -434.80M | $ -543.81M | $ -3.88B |
| EBITDA | $ -486.83M | $ -532.86M | $ -269.77M | $ -259.25M | $ -3.86B |
| Net Income | $ -509.11M | $ -515.24M | $ -359.36M | $ -308.12M | $ -3.90B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.96B | $ 2.16B | $ 2.72B | $ 3.18B | $ 3.52B |
| Total Assets | $ 4.22B | $ 3.77B | $ 3.88B | $ 3.93B | $ 3.93B |
| Total Debt | $ 788.88M | $ 753.24M | $ 418.71M | $ 121.97M | $ 39.26M |
| Net Debt | $ 245.71M | $ 334.82M | $ -432.32M | $ -482.10M | $ -1.48B |
| Total Liabilities | $ 1.44B | $ 1.29B | $ 896.11M | $ 593.10M | $ 289.07M |
| Stockholders' Equity | $ 2.78B | $ 2.47B | $ 2.99B | $ 3.34B | $ 3.65B |
| Cash Flow | |||||
| Free Cash Flow | $ -1.05B | $ -1.00B | $ -686.23M | $ -681.48M | $ -387.50M |
| Operating Cash Flow | $ -712.41M | $ -789.63M | $ -303.62M | $ -401.93M | $ -214.64M |
| Investing Cash Flow | $ 39.08M | $ 67.71M | $ 468.20M | $ -645.59M | $ -2.04B |
| Financing Cash Flow | $ 788.72M | $ 283.90M | $ 72.13M | $ -8.06M | $ 3.64B |
Currency in CNY